Company: CRL
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001100682-25-000034
Chunk: 39

Company: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Filing Date: 2025-08-06
Form: 10-Q
Item: Item 2
Chunk 39
---
 EndedJune 28, 2025June 29, 2024(in thousands)Capital expenditures$(94,622)$(118,630)Investments, net(5,984)(23,179)Proceeds from sale of businesses and assets, net17,441 — Acquisition of businesses and assets, net of cash acquired$— $(5,479)Other, net347 (370)Net cash used in investing activities$(82,818)$(147,658)

Investing activities primarily consist of cash used to fund capital expenditures to support the growth of our business, purchases and sales of investments related to our venture capital and strategic equity investment portfolios, and asset and business acquisitions, periodically offset by cash from divestitures.

For the six months ended June 28, 2025, cash used in investing activities was primarily driven by capital expenditures partially offset by proceeds from divestitures of certain site and business assets. Capital expenditures decreased for the six months ended June 28, 2025 as compared to the same period in 2024, as a result of disciplined spend management in light of the global economic environment.

For the six months ended June 29, 2024, cash used in investing activities was primarily driven by capital expenditures to support the growth of the business, an immaterial asset acquisition, and investments in certain venture capital and strategic equity investments.

35 

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

The following table presents our net cash (used in) provided by financing activities:

Six Months EndedJune 28, 2025June 29, 2024(in thousands)Proceeds from long-term debt and revolving credit facility$963,363 $741,200 Payments on long-term debt, revolving credit facility, and finance lease obligations(887,706)(987,344)Proceeds from exercises of stock options 1 22,331 Purchase of treasury stock(360,484)(18,265)Payment of contingent considerations(21,822)— Purchase of remaining equity interest of other redeemable noncontrolling interest(19,140)(12,000)Other, net(6,458)(13,434)Net cash used in financing activities$(332,246)$(267,512)

Financing activities primarily consist of the proceeds and repayments of debt and certain equity related transactions including treasury stock purchases and employee stock option exercises. 

For the six months ended June 28, 2025, net cash used in financing activities was